HCMSG The Hepatitis C Mentor & Support Group, Inc.
Search
  • Home
  • About Us
    • Our Mission
    • Board of Directors
  • Resources
    • Hep C Facts & Stats
    • Patient Assistance Programs
    • Research and Publications
    • Reading
    • Links
  • Programs/Training
    • The Hepatitis C Education and Support Group Assistance Program
    • The Circle Model >
      • THE CIRCLE Registration
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
  • Contact Us

BLOOD TESTS OK FOR FIBROSIS DX IN HEPATITIS C

6/11/2013

3 Comments

 
Blood Tests OK for Fibrosis Dx in Hep C
By Salynn  Boyles, Contributing Writer, MedPage
Today
Published: June 03,
2013
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman
School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA,
BSN, RN, Nurse Planner
Action Points


  • While liver biopsy remains the gold standard for predicting disease
    progression in people with HCV infection, it is no longer recommended as
    necessary in all patients before the initiation of antiviral therapy with newer
    medications.

  • This study suggests that blood tests can help to identify HCV-infected
    patients with clinically significant fibrosis, with somewhat greater accuracy
    for identifying cirrhosis than for less advanced
    fibrosis.


Blood testing can accurately identify clinically significant fibrosis and
cirrhosis in people with hepatitis C virus (HCV) infection and may be an
alternative to liver biopsy in some patients, a new study found.


The analysis of 172 studies comparing various blood tests to biopsy in HCV
patients revealed that some of the simplest, cheapest blood tests performed as
well as more expensive, complex tests, reported Roger Chou, MD, and Ngoc Wasson,
MPH, from the Evidence-Based Practice Center at Oregon Health and Science
University in Portland.


Six tests identified clinically meaningful fibrosis with a median positive
likelihood ratio of 5 to 10 at commonly used cutoffs and areas under the
receiver-operating characteristic curve (AUROCs) of 0.70 or greater (range 0.71
to 0.86), they wrote in the June 4 issue of the Annals of Internal
Medicine.



The tests were the platelet count, age-platelet index, aspartate
aminotransferase-platelet ratio index (APRI), FibroIndex, FibroTest, and Forns
index.


In addition, three of those tests, platelet count, age-platelet index, APRI,
plus Hepascore, all identified cirrhosis with median positive likelihood ratios
of 5 to 10 and AUROCs of 0.80 or greater (range 0.80 to 0.91).


"Our results suggest that blood tests can help to identify HCV-infected
patients with clinically significant fibrosis, with somewhat greater accuracy
for identifying cirrhosis than for less advanced fibrosis," the researchers
wrote.


Liver biopsy remains the gold standard for predicting disease progression in
people with HCV infection, but it is no longer recommended in all patients
before the initiation of antiviral therapy. Drawbacks of liver biopsy include
the potential for sampling error and risk for complications such as bleeding,
severe pain, and infection,


Blood tests have been proposed as a less invasive alternative to liver
biopsy, and more than two dozen tests have been studied for this purpose.


"We expect to see all-oral, interferon-free HCV treatment regimens in a few
years, and that means many more people are likely to begin antiviral therapies,"
they wrote. "Having blood tests to help identify patients who can benefit from
these treatments will be increasingly important."


Using MEDLINE, the Cochrane Library database, and other reference lists, the
authors identified studies that compared blood tests to liver biopsy for
diagnosing fibrosis or cirrhosis in HCV-infected people.


Most of the studies included in the analysis were conducted in the U.S.,
Europe, Asia and northern Africa, and 15 were rated as good quality studies,
while five were rated poor quality. The remainder were considered fair
quality.


Chou said one of the most surprising findings was that the simple APRI blood
test performed as well or better than more complex and expensive tests.


"This test provided useful information about the severity of underlying liver
disease," he told MedPage Today. "For patients trying to decide if they
should begin antiviral therapy, this and other blood tests may be an alternative
to biopsy."


In a subanalysis in which APRI was compared to FibroTest (known as FibroSure
in the U.S.), the predictive value of the two tests was very similar, Chou
said.


FibroTest is a patented, six blood serum test for liver damage marketed by
French company BioPredictive.


APRI was associated with a slightly lower AUROC than the FibroTest for
fibrosis (18 studies: median difference, -0.03; range, minus 0.10-0.07), but
there was no difference for cirrhosis (seven studies; median difference, 0.0;
range, minus 0.04 to 0.06).


Chou and Wasson noted several limitations to their analysis, including the
fact that only English-language studies were included and that most trials
failed to describe blinded interpretation of liver biopsy specimens. Many also
included inadequate descriptions of enrollment methods.


The added that the results may not apply to populations excluded from the
review, including patients coinfected with hepatitis B virus, HIV, and those
receiving hemodialysis.



The study was funded by a grant from the Agency for Healthcare Research and
Quality.







Primary source: Annals of Internal Medicine
             Source
reference:
Chou R, et al "Blood tests to diagnose fibrosis or cirrhosis in
patients with chronic hepatitis c virus infection" Ann Intern Med 2013;
158.



 
 
 
 


 
3 Comments
superior paper link
6/27/2013 09:58:27 pm

I really enjoy simply reading all of your weblogs. Simply wanted to inform you that you have people like me who appreciate your work. Definitely a great post. Hats off to you! The information that you have provided is very helpful.

Reply
creer site internet link
7/6/2013 12:17:09 am

I appreciate, cause I found exactly what I used to be looking for. You have ended my four day long hunt! God Bless you man. Have a nice day.

Reply
ranch rails link
10/20/2013 10:48:47 pm

The added that the results may not apply to populations excluded from the
review, including patients coinfected with hepatitis B virus, HIV, and those
receiving hemodialysis.

Reply

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy